Profile of soluble cytokine receptors in Crohn's disease
Profile of soluble cytokine receptors in Crohn's disease
复制标题
DOI：
10.1136/gut.2004.043554
复制
发表时间：
2005-04-01
期刊：
影响因子：
24.5
通讯作者：
Franchimont, D
中科院分区：
文献类型：
--
作者：
Gustot, T;Lemmers, A;Franchimont, D
引言：可溶性细胞因子受体（sCR）调节细胞因子的体内活性。sCR产生缺陷可能参与克罗恩病（CD）的发病和病程。本研究的目的是研究的配置文件的sCRs在CD患者和他们的调制英夫利西单抗和皮质类固醇。方法：我们前瞻性地研究了活动性CD患者（aCD）治疗英夫利西单抗（n=21）或皮质类固醇（n=9），CD患者的临床缓解（rCD，n=20），溃疡性结肠炎患者（UC，n=24），和健康受试者（HS，n=15）。还检查了CD炎症（n=8）、CD非炎症（n=7）和健康粘膜（n=8）的结肠活检组织培养物。采用ELISA法检测肿瘤坏死因子α（TNF-α）、可溶性TNF受体I（sTNFRI）、可溶性TNF受体II（sTNFRII）、白细胞介素1 β（IL-1 β）、可溶性IL-1受体I（sIL-1 RI）、可溶性IL-1受体II（sIL-1 RII）、IL-6、可溶性IL-6受体（sIL-6 R）和sgp 130的水平。
Introduction: Soluble cytokine receptors (sCRs) modulate the in vivo activity of cytokines. Deficient sCR production could participate in the pathogenesis and course of Crohn's disease ( CD). The aim of the study was to examine the profile of sCRs in CD patients and their modulation by infliximab and corticosteroids.Methods: We prospectively examined active CD patients (aCD) treated with either infliximab (n=21) or corticosteroids (n=9), CD patients in clinical remission (rCD, n=20), ulcerative colitis patients (UC, n=24), and healthy subjects (HS, n=15). Cultures of colonic biopsies were also examined from CD inflamed (n=8), CD non-inflamed (n=7), and healthy mucosa (n=8). Levels of tumour necrosis factor alpha (TNF-alpha), soluble TNF receptor I (sTNFRI), soluble TNF receptor II (sTNFRII), interleukin 1 beta (IL-1 beta), soluble IL-1 receptor I (sIL-1RI), soluble IL-1 receptor II (sIL-1RII), IL-6, soluble IL-6 receptor (sIL-6R), and sgp130 were measured using ELISA.Results: Higher levels of sTNFRI (p